Search Results
Feb 16, 2026, 20:59 ET RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit
of the case: According to the lawsuit, defendants provided investors with material information concerning Ultragenyx's expected results for its Phase III Orbit and Cosmic Studies, which tested setrusumab (UX 143) in patients with Osteogenesis Imperfecta ("OI"). Defendants' statements included, among other
More news about: THE ROSEN LAW FIRM, P.A.
Feb 16, 2026, 18:01 ET FIBRA Prologis Declara Distribución del Trimestre
situación económica internacional, regional y local, (ii) los cambios en los mercados financieros, tasas de interés y tipos de cambio de moneda extranjera, (iii) aumento en, o surgimiento de, competencia respecto de nuestras propiedades, (iv) los riesgos asociados con adquisiciones, enajenación y desarrollo de
More news about: FIBRA Prologis
Feb 16, 2026, 17:59 ET FIBRA Prologis Declara Distribución del Trimestre
situación económica internacional, regional y local, (ii) los cambios en los mercados financieros, tasas de interés y tipos de cambio de moneda extranjera, (iii) aumento en, o surgimiento de, competencia respecto de nuestras propiedades, (iv) los riesgos asociados con adquisiciones, enajenación y desarrollo de
More news about: FIBRA Prologis
Feb 16, 2026, 17:33 ET FIBRA Prologis Declares Quarterly Distribution
national, international, regional and local economic climates, (ii) changes in financial markets, interest rates and foreign currency exchange rates, (iii) increased or unanticipated competition for our properties, (iv) risks associated with acquisitions, dispositions and development of properties, (v)
More news about: FIBRA Prologis
Feb 16, 2026, 17:31 ET Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
therapy to selectively inhibit and reduce pathogenic T cells by acting on the OX40 receptor. According to Amgen's Q3 2025 financial report, the Phase III ROCKET program, comprising eight studies assessing rocatinlimab in patients with moderate-to-severe atopic dermatitis, has enrolled over 3,300 participants,
More news about: DelveInsight Business Research, LLP
Feb 16, 2026, 16:40 ET Wheaton Precious Metals Announces Acquisition of Additional Silver Stream on Antamina Through New Partnership with BHP
announced February 16, 2026; (ii) production payments per ounce (pound) of metal received determined under applicable precious metals purchase agreements; (iii) 2026 and long-term commodity price assumptions of $4,800 / oz gold, $80 / oz silver, $1,500 / oz palladium, $2,000 / oz platinum, and $25 / lb cobalt,
More news about: Wheaton Precious Metals Corp.
Feb 16, 2026, 10:00 ET Thompson Thrift Announces Sale of Notch66 Multifamily Community Near Boulder, Colorado
Notch66 was developed with equity from Watermark 2021 Development Fund III, LP. Construction began in February 2022 and was completed in June 2024. At the time of sale, Notch66 was 93% leased."The successful sale of Notch66
More news about: Thompson Thrift
Feb 16, 2026, 09:00 ET Data Presented at SABCS 2025 Demonstrated that the Endocrine Activity Index® (EAI®) May Identify Patients Most Likely to Benefit from Extended Endocrine Therapy
Activity Index® (EAI™) test can provide actionable information for prognosis and prediction of dose-intense taxane-based chemotherapy benefit in stage II-III, HR+ HER2- breast cancer. The EAI measures endocrine activity in a breast tumor and for prognostic use, the Index Score is adjusted for baseline prognosis
More news about: Delphi Diagnostics Inc
Feb 16, 2026, 08:00 ET Bernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Publicly Traded Origin Materials Securities
the proposed Settlement as fair, reasonable, and adequate; (ii) dismiss the Action with prejudice as provided in the Stipulation of Settlement; and (iii) approve Lead Counsel's motion for attorneys' fees and Litigation Expenses. The Court may change the date of the Settlement Hearing, or hold it telephonically
More news about: Bernstein Liebhard LLP
Feb 15, 2026, 14:10 ET ARDT INVESTOR DEADLINE: Ardent Health, Inc. Investors with Substantial Losses Have Opportunity to Lead the Ardent Health Class Action Lawsuit
allowed Ardent Health to report higher amounts of accounts receivable during the Class Period, and delay recognizing losses on uncollectable accounts; (iii) consequently, Ardent Health's reported financial position was materially false and misleading; (iv) Ardent Health did not maintain professional malpractice
More news about: Robbins Geller Rudman & Dowd LLP
Feb 13, 2026, 22:19 ET Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Company announced the "results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta" disclosing that both its Phase III Orbit and Cosmic studies failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates for patients
More news about: Kahn Swick & Foti, LLC
Feb 13, 2026, 22:13 ET CoreWeave, Inc. Notice of March 13, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
severity of the risk that its reliance on a single third-party data center supplier created for its ability to meet customer demand for its services; (iii) the foregoing was reasonably likely to have a material negative impact on the Company's revenue; and (iv) as a result, CoreWeave's public statements
More news about: Kahn Swick & Foti, LLC
Feb 13, 2026, 18:01 ET Breakthrough Study Confirms HYD LLC's 30-Year Research on Deuterium Modulation in Cancer Gene Expression
anticancer treatments based on isotopic modulation. HYD LLC is actively seeking investment partners and pharmaceutical collaborators to conduct Phase II/III clinical trials and complete drug registration.HYD LLC has announced that registration is now open for the 5th International Congress on Deuterium
More news about: HYD LLC
Feb 13, 2026, 16:53 ET EUROPÄISCHE KOMMISSION GENEHMIGT UPLIZNA® VON AMGEN FÜR GENERALISIERTE MYASTHENIA GRAVIS
Screening sowie bei der Randomisierung gehörten eine Klassifikation gemäß der Myasthenia Gravis Foundation of America (MGFA) als Erkrankung der Stufen II, III oder IV, ein MG-ADL-Score zwischen 6 und 10, wobei mehr als 50 % dieses Scores auf nicht okulare Kriterien entfallen mussten, oder ein MG-ADL-Score von
More news about: Amgen
Feb 13, 2026, 16:15 ET HONEYWELL ANNOUNCES QUARTERLY DIVIDEND
conditions related thereto; (ii) the possibility that the spin-off transaction will not be completed within the anticipated time period or at all; (iii) the possibility that the spin-off transaction will not achieve its intended benefits; (iv) the impact of the spin-off transaction on Honeywell's businesses
More news about: Honeywell
Feb 13, 2026, 16:10 ET FRMI INVESTOR DEADLINE: Fermi Inc. Investors with Substantial Losses Have Opportunity to Lead the Fermi Class Action Lawsuit
campus; (ii) the extent to which Project Matador would rely on a single tenant's funding commitment to finance the construction of Project Matador; and (iii) that there was a significant risk that the tenant would terminate its funding commitment.The Fermi class action lawsuit further alleges
More news about: Robbins Geller Rudman & Dowd LLP
Feb 13, 2026, 14:41 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK UPLIZNA® OD SPOLOČNOSTI AMGEN NA LIEČBU GENERALIZOVANEJ MYASTÉNIE GRAVIS
190 pacientov s AChR+ a 48 pacientov s MuSK+.5Kritériá oprávnenosti pri skríningu a randomizácii zahŕňali klasifikáciu ochorenia II, III alebo IV podľa Myasthenia Gravis Foundation of America (MGFA), skóre MG-ADL od 6 do 10, pričom viac ako 50 % tohto skóre bolo pripísaných neokulárnym
More news about: Amgen
Feb 13, 2026, 12:47 ET FIBRA Prologis Anuncia Conferencia Telefónica donde Presentará los Resultados Financieros del Cuarto Trimestre de 2025 el 24 de Febrero
situación económica internacional regional y local, (ii) los cambios en los mercados financieros, tasas de interés y tipos de cambio de moneda extranjera, (iii) aumento en, o surgimiento de, competencia respecto de nuestras propiedades, (iv) los riesgos asociados con adquisiciones, enajenación y desarrollo de
More news about: FIBRA Prologis
Feb 13, 2026, 12:44 ET FIBRA Prologis Anuncia Conferencia Telefónica donde Presentará los Resultados Financieros del Cuarto Trimestre de 2025 el 24 de Febrero
situación económica internacional regional y local, (ii) los cambios en los mercados financieros, tasas de interés y tipos de cambio de moneda extranjera, (iii) aumento en, o surgimiento de, competencia respecto de nuestras propiedades, (iv) los riesgos asociados con adquisiciones, enajenación y desarrollo de
More news about: FIBRA Prologis
Feb 13, 2026, 12:25 ET FIBRA Prologis to Host Fourth Quarter 2025 Earnings Conference Call February 24
national, international, regional and local economic climates, (ii) changes in financial markets, interest rates and foreign currency exchange rates, (iii) increased or unanticipated competition for our properties, (iv) risks associated with acquisitions, dispositions and development of properties, (v)
More news about: FIBRA Prologis
Feb 13, 2026, 12:00 ET Black Diamond Capital Management Announces Palisades Center Long Term Ownership and Operational Plans
approximately $11 billion in assets under management across four core platforms: (i) distressed and special situations private equity funds; (ii) hedge funds; (iii) non-control stressed and distressed closed-ended funds; and (iv) collateralized loan obligations and structured products. Black Diamond has over 25
More news about: Black Diamond Capital Management
Feb 13, 2026, 11:47 ET ЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРИЛА ПРЕПАРАТ AMGEN UPLIZNA ® ДЛЯ ЛЕЧЕНИЯ ГЕНЕРАЛИЗОВАННОЙ МИАСТЕНИИ
пациентов с AChR+ и 48 пациентов с MuSK+.5Критерии приемлемости при скрининге и рандомизации включали классификацию заболевания II, III или IV по классификации Американского фонда миастении гравис (MGFA), балл по шкале MG-ADL от 6 до 10, причем более 50% этого балла относилось к невизуальным
More news about: Amgen
Feb 13, 2026, 11:41 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK UPLIZNA® SPOLEČNOSTI AMGEN PRO GENERALIZOVANOU MYASTENII GRAVIS
MuSK+.5Kritéria způsobilosti při screeningu a randomizaci zahrnovala klasifikaci onemocnění od Myasthenia Gravis Foundation of America (MGFA) II, III nebo IV, skóre MG-ADL mezi 6 a 10 s více než 50 % tohoto skóre připadajícího na neokulární položky nebo skóre MG-ADL nejméně 11 a kvantitativní skóre
More news about: Amgen
Feb 13, 2026, 11:00 ET Open Pontoon Boat Market Poised for Steady Expansion from USD 1.5 Billion in 2024 to USD 2.3 Billion by 2033, Supported by Rising Recreational Boating Demand : - Market Research Intellect
Channel Opener Market By Product (Type I (Small‑Molecule Therapeutics), Type II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare
More news about: Market Research Intellect
Feb 13, 2026, 10:39 ET Electronic Discovery Software Market to Reach USD 10.1 Billion by 2033, Fueled by Rising Digital Litigation, Regulatory Compliance Needs, and Advanced Analytics Adoption: Market Research Intellect
Channel Opener Market By Product (Type I (Small‑Molecule Therapeutics), Type II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare
More news about: Market Research Intellect